According to the Wise Finance APP, on Friday, the biopharmaceutical company Camp4 Therapeutics (CAMP.US), supported by medical giant Kaiser Permanente, debuted on nasdaq, opening up more than 1% at $11.16, with an IPO price of $11. This company, located in Cambridge, Massachusetts, is developing therapies for various genetic diseases. Its main candidate product CMP-CPS-001 is used to treat the most common urea cycle disorders and is currently being evaluated in early clinical trials.